Friday, September 30, 2022


Biotechnology News Magazine

NIH Awards Matregenix a Phase 1 SBIR Grant to Develop a New Dental Barrier Membrane for Guided Bone Regeneration

Matregenix is headquartered at University Lab Partners, the premier life science incubator located in UCI Research Park.

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Matregenix announces a grant award from the National Institute of Dental & Craniofacial Research under the auspices of the Small Business Innovation Research (SBIR) program and National Institutes of Health (NIH). The grant will be utilized to develop a new dental barrier membrane for guided bone regeneration.

Guided bone regeneration (GBR) is a common technique used in the dental industry for the treatment of bony defects, among other conditions. Barrier membranes are crucial components of GBR procedures, used to cover the bone defect and create a secluded space that facilitates growth of the bone by preventing connective tissue from interfering in that growth while also protecting the wound. Legacy membranes fall short of attaining the desired properties for GBR techniques leading to additional costs and unnecessary pain for patients.

“Our new approach will address the limitations of current products by eliminating the need for animal-based materials while introducing a new biomaterial to benefit the areas of soft tissue repair applications. This award will help us validate the clinical significance of our innovative membrane to provide a more suitable armamentarium for oral and craniomaxillofacial bone regeneration compared to the gold standard collagen membrane,” stated Dr. Sherif Soliman, Founder and CEO of Matregenix.

The research will be conducted in collaboration with Prof. Marco Bottino’s research group from the University of Michigan. “This project is built on the extensive published and preliminary data that my lab has generated in collaboration with Matregenix over the past 3 years, and I strongly believe that successful completion of this project is the critical step to translating the next-generation of barrier membranes for guided bone regeneration applications,” stated Prof. Marco Bottino, University of Michigan School of Dentistry.

Matregenix has also been recognized as a finalist in the 2022 High Tech Awards powered by Octane. In addition, the Matregenix Transparent Nanofiber Mask was announced as a Phase 2 finalist in the Biomedical Advanced Research and Development Authority (BARDA)-NIOSH-NIST Mask Innovation Challenge.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine